Michel Vounatsos (Credit: World Economic Forum/Valeriano Di Domenico)
May 3, 2022 11:17 AM EDTUpdated 02:22 PM
Deals
Bioregnum

As Bio­gen hunts for a turn­around CEO, ex­ecs sketch out a hazy look at an un­cer­tain new fu­ture

Once again, Bio­gen’s board of di­rec­tors is look­ing to ex­e­cute a brisk turn­around in or­der to sat­is­fy in­vestors that it has a sol­id foot­ing and …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

Meet the ‘first sale’ rule: A cus­toms loop­hole phar­ma com­pa­nies could use to ease tar­iff im­pact

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times